Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety.

Garcia DE Lucas MD, Perez-Belmonte L, Aviles-Bueno B, Jimenez-Millan A, Rivas Ruiz F, Miramontes-González JP

Minerva endocrinology20 Jun 2023Cited by 2 (Europe PMC)

PMID37337740DOI10.23736/s2724-6507.23.03985-4PepBankPUB-37337740

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In adults over 70 years with type 2 diabetes, once-weekly semaglutide reduced HbA1c by 0.61% after 12 months.
In plain wordsIn adults over 70 with type 2 diabetes, weekly semaglutide lowered HbA1c after 12 months.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at 12 months
Study
n = 60
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−0.61%
total cohort
Source sentences
Summary
After 12 months of follow-up, the reductions in HbA1c were -0.61±0.9% (P<0.0001) in the total cohort.
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was the change in HbA1c from baseline to the end of the study.
Summary · context
It included 60 patients with T2DM, with a mean age of 76.5 years, 63.3% women, and a mean of 15.5 years of evolution of T2DM, all managed in the outpatient clinical setting.
Report a problemFND-3733774001
02HumanObservational studyEfficacy outcome
In adults over 70 years with type 2 diabetes, once-weekly semaglutide reduced body weight by 8.2 kg after 12 months.
In plain wordsIn adults over 70 with type 2 diabetes, weekly semaglutide lowered body weight after 12 months.
Peptide
Semaglutide
Outcome
DecreaseBody weight change at 12 months
Study
n = 60
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Body weight change
−8.2 kg
total cohort
Source sentences
Summary
Body weight reductions were -8.2±5.3 kg (P<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The secondary endpoints included changes in body weight and the proportion of patients achieving HbA1c 5%.
Summary · context
It included 60 patients with T2DM, with a mean age of 76.5 years, 63.3% women, and a mean of 15.5 years of evolution of T2DM, all managed in the outpatient clinical setting.
Report a problemFND-3733774002
03HumanObservational studyEfficacy outcome
In adults over 70 years with type 2 diabetes, 67% reached an HbA1c below 7% on once-weekly semaglutide.
In plain wordsIn adults over 70 with type 2 diabetes, 67% reached an HbA1c below 7% on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion reaching HbA1c below 7%
Study
n = 60
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Proportion with HbA1c <7%
67%
total cohort
Source sentences
Summary
Overall, 67% reached the objective of an HbA1c level of <7%, and 73% achieved a weight loss of ≥5%.
2 context sentences(design, population, supporting numbers)
Summary · context
The secondary endpoints included changes in body weight and the proportion of patients achieving HbA1c 5%.
Summary · context
It included 60 patients with T2DM, with a mean age of 76.5 years, 63.3% women, and a mean of 15.5 years of evolution of T2DM, all managed in the outpatient clinical setting.
Report a problemFND-3733774003
04HumanObservational studyEfficacy outcome
In adults over 70 years with type 2 diabetes, 73% lost at least 5% of body weight on once-weekly semaglutide.
In plain wordsIn adults over 70 with type 2 diabetes, 73% lost at least 5% of their weight on weekly semaglutide.
Peptide
Semaglutide
Outcome
Not applicableProportion with weight loss of 5% or more
Study
n = 60
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Proportion with weight loss >=5%
73%
total cohort
Source sentences
Summary
Overall, 67% reached the objective of an HbA1c level of <7%, and 73% achieved a weight loss of ≥5%.
2 context sentences(design, population, supporting numbers)
Summary · context
The secondary endpoints included changes in body weight and the proportion of patients achieving HbA1c 5%.
Summary · context
It included 60 patients with T2DM, with a mean age of 76.5 years, 63.3% women, and a mean of 15.5 years of evolution of T2DM, all managed in the outpatient clinical setting.
Report a problemFND-3733774004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.